¿Qué es la narcolepsia?

[1] Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (Orexin) deficiency in human narcolepsy. Lancet. 2000;355(9197):39–40. [PubMed]
[2] Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretinneurons in human narcolepsy. Neuron. 2000;27(3):469–74. [PubMed]
[3] Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med. 2000;6(9):991–97. [PubMed]
[4] Hong SC, Lin L, Jeong JH, et al. A study of the diagnostic utility of HLA typing, CSF hypocretin-1 measurements, and MSLT testing for the diagnosis of narcolepsy in 163 Korean patients with unexplained excessive daytime sleepiness. Sleep. 2006;29(11):1429–38. [PubMed]
[5] Mignot E, Hayduk R, Black J, Grumet FC, Guilleminault C. HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep. 1997; Nov;20(11):1012–20. [PubMed]
[6] Yoss RE, Daly DD. Criteria for the diagnosis of the narcoleptic syndrome. Proc Staff Meeting Mayo Clinic. 1957;32:320–28. [PubMed]
[7] Richardson GS, Carskadon MA, Flagg W, van den Hoed J, Dement WC, Mitler MM. Excessive daytime sleepiness in man: multiple sleep latency measurement in narcoleptic and control subjects. Electroencephalogr. Clin. Neurophysiol. 1978;45:621–27. [PMC free article] [PubMed]
[8] Honda Y, Asake A, Tanaka Y, Juji T. Discrimination of narcolepsy by using genetic markers and HLA. Sleep Res. 1983;1(2):254.
[9] Silber MH, Krahn LE, Olson EJ, Pankratz VS. The epidemiology of narcolepsy in Olmsted County, Minnesota: A population-based study. Sleep. 2002;25(2):197–202. [PubMed]
[10] Heier MS, Evsiukova T, Wilson J, Abdelnoor M, Hublin C, Ervik S. Prevalence of narcolepsy with cataplexy in Norway. Acta Neurol Scand. 2009;120(4):276–80. [PubMed]
[11] Overeem S, Mignot E, van Dijk JG, Lammers GJ. Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives. J Clin Neurophysiol. 2001;18:78–105. [PubMed]
[12] Picchioni D, Mignot EJ, Harsh JR. The month-of-birth pattern in narcolepsy is moderated by cataplexy severity and may be independent of HLA-DQB1*0602. Sleep. 2004;27(8):1471–5. [PubMed]
[13] Siebold C, Hansen B E, Wyer J R, Harlos K, Esnouf R E, Svejgaard A, et al. Crystal structure of HLA-DQ0602 that protects against type 1 diabetes and confers strong susceptibility to narcolepsy. Proc Nat Acad Sci. 2004;101 [PMC free article] [PubMed]
[14] Mignot E, Lin X, Arrigoni J, et al. DQB1*0602 and DQA1*0102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and black Americans. Sleep. 1994;17:S6–S7. [PubMed]
[15] Billiard M, Pasquie-Magnetto V, Heckman M, et al. Family studies in narcolepsy. Sleep. 1994;17:S54–S59. [PubMed]
[16] Tafti M. Genetic aspects of normal and disturbed sleep. Sleep Med. 2009;10(Suppl 1):S17–S21. [PubMed]
[17] Peacock J, Benca RM. Narcolepsy: Clinical features, co-morbidities and treatment. Indian J Med Res. 2010;131:338–49. [PubMed]
[18] Nuñez ML, Rodrigo-Angulo I, De Andrés, Garzón M. Hypocretin/orexin neuropeptides: participation in the control of sleep-wakefulness cycle and energy homeostasis. Curr Neuropharmacol. 2009;7(1):50–59. [PMC free article] [PubMed]
[19] Thannickal TC, Nienhuis R, Siegel JM. Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy. Sleep. 2009;32:993–8. [PMC free article] [PubMed]
[20] Foutz AS, Mitler MM, Cavalli-Sforza LL, Dement WC. Genetic factors in canine narcolepsy. Sleep. 1979;1(4):413–21. [PubMed]
[21] Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (Orexin) receptor 2 gene. Cell. 1999;98:365–76. [PubMed]
[22] Bourgin P, Zeitzer JM, Mignot E. Review: CSF hypocretin-1 assessment in sleep and neurological disorders. Lancet Neurol. 2008;7(7):649–62. [PubMed]
[23] Nepom GT. Monoclonal Antibodies and Peptide Therapy in Autoimmune Diseases. New York: Marcel Dekker; 1993. MHC and autoimmune diseases. In: Bach J-F, ed; pp. 143–64.
[24] Cvetkovic-Lopes V, Bayer L, Dorsaz S, et al. Elevated tribbles homolog 2-specific antibody levels in narcolepsy patients. J Clin Invest. 2010;120(3):713–19. [PMC free article] [PubMed]
[25] Hallmayer J, Faraco J, Lin L, et al. Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet. 2009;41(6):708–11. [PMC free article] [PubMed]
[26] Himmerich H, Beitinger PA, Fulda S, et al. Plasma levels of tumornecrosisfactor alpha and soluble tumor necrosis factor receptors in patients with narcolepsy. Arch Intern Med. 2006;166(16):1739–43. [PubMed]
[27] Kawashima M, Lin L, Tanaka S, Jennum P, Knudsen S, Nevsimalova S, et al. Anti-Tribbles homolog 2 (TRIB2) autoantibodies in narcolepsy are associated with recent onset of cataplexy. Sleep. 2010;33:869–74. [PMC free article] [PubMed]
[28] Smith AJ, Jackson MW, Neufing P, McEvoy RD, Gordon TP. Afunctional autoantibody in narcolepsy. Lancet. 2004;364:2122–4. [PubMed]
[29] Kornum BR, Kawaswhima M, Faraco J, et al. Common variants in P2RY11 are associated with narcolepsy. Nat Genet. 2011;43(10):1040. [PMC free article] [PubMed]
[30] Watson NF, Ton TG, Koepsell TD, Longstreth WT Jr. Birth order and narcolepsy risk among genetically susceptible individuals: a population-based case-control study. Sleep Med. 2012;13(3):310–3. [PMC free article] [PubMed]
[31] Wijnans L, et al. The incidence of narcolepsy in Europe: before, during, and after the influenza A (H1N1) pdm09 pandemic and vaccination campaigns. Vaccine. 2012;31:1246–54. [PubMed]
[32] Fontana A, Gast H, Reith W, Recher M, Birchler T, Bassetti CL. Narcolepsy: Autoimmunity, effector T cell activation due to infection, or T cell independent, major histocompatibility complex class II induced neuronal loss? Brain. 2010;133(Pt 5):1300–11. [PubMed]
[33] Burgess CR, Scammell TE. Narcolepsy: Neural mechanisms of sleepiness and cataplexy. J Neurosci. 2012;32(36):12305–311. [PMC free article] [PubMed]
[34] Aran A, Lin L, Nevsimalova S, et al. Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep. 2009;32:979–83. [PMC free article] [PubMed]
[35] Dale RC. Post-streptococcal autoimmune disorders of the central nervous system. Dev Med Child Neurol. 2005;47:785–91. [PubMed]
[36] Han F, et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol. 2011;70:410–17. [PubMed]
[37] Miller E, Andrews N, Stellitano L, Stowe J, Winstone AM, Shneerson J, Verity C. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: Retrospective analysis. BMJ (Online) 2013;346(7897) art. no. f794. [PubMed]
[38] ECDC technical report, 2013. Narcolepsy in association with pandemic influenza vaccination: A multi-country European epidemiological investigation.
[39] Ton TG, Longstreth WT Jr, Koepsell TD. Environmental toxins and risk of narcolepsy among people with HLA DQB1*0602. Environ Res. 2010;110(6):565–70. [PMC free article] [PubMed]
[40] Nevsimalova S, et al. Narcolepsy: clinical differences and association with other sleep disorders in different age groups. J Neurol. 2012;260:767–75. [PubMed]
[41] Nightingale S, Orgill JC, Ebrahim IO, de Lacy SF, Agrawal S, Williams AJ. The association between narcolepsy and REM behaviour disorder (RBD) Sleep Med. 2005;6(3):253–8. [PubMed]
[42] Wierzbicka A, Wichniak A, Waliniowska E, Czasak K, Musi Ska I, Szatkowska E, et al. REM sleep behaviour disorder in narcolepsy. Neurol Neurochir Pol. 2009;43(5):421–7. [PubMed]
[43] Dauvilliers Y, Pennestri MH, Petit D, Dang-Vu T, Lavigne G, Montplaisir J. Periodic leg movements during sleep and wakefulness in narcolepsy. J Sleep Res. 2007;16(3):333–9. [PubMed]
[44] Honda Y, Doi Y, Ninomiya R, Ninomiya C. Increased frequencyof non-insulin-dependent diabetes mellitus among narcoleptic patients. Sleep. 1986;9:254–9. [PubMed]
[45] Schuld A, Hebebrand J, Geller F, Pollmacher T. Increased bodymass index in patients with narcolepsy. Lancet. 2000;355:1274–5. [PubMed]
[46] Okun ML, Lin L, Pelin Z, Hong S, Mignot E. Clinical aspects of narcolepsy-cataplexy across ethnic groups. Sleep. 2002 Feb 1;25(1):27–35. [PubMed]
[47] Sonka K, Kemlink D, Busková J, Pretl M, Srtková Z, Maurovich Horvat E, et al. Obesity accompanies narcolepsy with cataplexy but not narcolepsy without cataplexy. Neuro Endocrinol Lett. 2010;31(5):631–4. [PubMed]
[48] Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell. 1999;98(4):437–51. [PubMed]
[49] Mochizuki T, Crocker A, McCormack S, Yanagisawa M, Sakurai T, Scammell TE. Behavioral state instability in orexin knock-out mice. J Neurosci. 2004;24:6291–6300. [PubMed]
[50] Soja PJ, Morales FR, Baranyi A, Chase MH. Effect of inhibitory amino acid antagonists on IPSPs induced in lumbar motoneurons upon stimulation of the nucleus reticularis gigantocellularis during active sleep. Brain Res. 1987;423:353–58. [PubMed]
[51] Boissard R, Gervasoni D, Schmidt MH, Barbagli B, Fort P, Luppi PH. The rat ponto-medullary network responsible for paradoxical sleep onset and maintenance: a combined microinjection and functional neuroanatomical study. Eur J Neurosci. 2002;16:1959–73. [PubMed]
[52] Wu MF, John J, Boehmer LN, Yau D, Nguyen GB, Siegel JM. Activity of dorsal raphe cells across the sleep-waking cycle and during cataplexy in narcoleptic dogs. J Physiol. 2004 Jan 1;554(Pt 1):202–15. [PMC free article] [PubMed]
[53] Yamuy J, Fung SJ, Xi M, Chase MH. Hypocretinergic control of spinal cord motoneurons. J Neurosci. 2004 Jun 9;24(23):5336–45. [PubMed]
[54] Kim SJ, Lyoo IK, Lee YS, Lee JY, Yoon SJ, Kim JE, et al. Gray matter deficits in young adults with narcolepsy. ActaNeurol Scand. 2009;119(1):61–7. [PubMed]
[55] Joo EY, Tae WS, Kim JH, Kim BT, Hong SB. Glucose hypo metabolism of hypothalamus and thalamus in narcolepsy. Ann Neurol. 2004;56(3):437–40. [PubMed]
[56] Brabec J, Rulseh A, Horinek D, Pala A, Guerreiro H, Buskova J, et al. Volume of the amygdala is reduced in patients with narcolepsy - a structural MRI study. NeuroEndocrinolLett. 2011;32(5):652–6. [PubMed]